Jim Cramer on Eli Lilly: "How Can You Leave This One Right Here?"

Eli Lilly and Company (NYSE:LLY) is one of the stocks in Jim Cramer’s spotlight. Answering a caller’s query about the company, Cramer said:

“Alright, listen to me. This one is one that everyone’s going to give up on. Then one day, it’s going to be up 300, I’m not kidding. That’s what happens with these stocks. You know, this stock went from $200 to $600, then went to $900, then came back to $700, then went up to $800. This thing is just a coiled spring when we get the new numbers. But don’t be too excited. There are many big studies coming down the pipe. A hypertension study, it’s going to be remarkable. There’s going to be heart failure, and there’s going to be Alzheimer’s study. How can you leave this one right here? I see plenty of people losing it, and they shouldn’t.”

Eli Lilly (NYSE:LLY) develops and markets a wide range of pharmaceuticals for diabetes, obesity, cancer, autoimmune diseases, mental health, and other conditions. The company also collaborates with multiple biotech firms to advance innovative treatments across various therapeutic areas.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.